December 2006, Vol 28, No. 12
Update Article

Investigation of ischaemic chest pain: which tests to choose?

John T H Wong 王泰鴻,Andy W K Chan 陳偉光

HK Pract 2006;28:530-539

Summary

Chest pain is a common symptom that prompts patient to present to a clinician. Clinicians not specializing in cardiology may become confused and overwhelmed by the wide range of newer investigations for the assessment of suspected ischaemic chest pain. These include multislice computed tomography, cardiac magnetic resonance imaging and coronary angiography complemented with intravascular ultrasound. Together with conventional tests like exercise electrocardiography, radionuclide imaging and stress echocardiography, they all provide the precise diagnosis with good to excellent accuracy and the severity of the underlying coronary artery disease. Some investigations allow deeper insights into the mechanism of various aspects of coronary artery disease and contribute important implications in the diagnostic and therapeutic strategies in treating coronary artery disease. Therefore, by choosing a series of most suitable tests for patients suffering from suspected ischaemic chest pain will allow the identification of those who are most at risk for adverse cardiovascular events and facilitate in deciding the most appropriate interventions and eventually improve their outcomes.

摘要

胸痛是促使病人求醫的常見病徵。作為非心臟專科醫生,可能會對不同種類,日新月異的冠心病醫療檢查方法感到迷惑,難以取捨。這些包括多層薄片電腦掃瞄、心臟磁共振成像,以及心臟血管造影術輔以血管內超聲波檢查。還有傳統的測試:運動心電圖、放射性核素成像和壓力心臟超聲波。它們都能為冠心病提供精確診斷,並對其嚴重程度作出評估。一些檢查更可讓我們進一步了解冠心病的各種機制,對診斷和治療提供很大的幫助。因此選擇適當的測試可辨認較為高危的心臟血管病病人,從而採用恰當的治療以達到更佳的效果。


Introduction

Chest pain is a very common presenting symptom in patients suffering from coronary artery disease (CAD). Prompt and efficient assessment of patients with chest pain is central to any strategy aiming to relieve their symptoms and improve their outcomes by providing them with appropriate treatment. Moreover, the investigation of patients with chest pain occupies a considerable amount of the resources of both general practitioners and cardiologists.

Routine workup by taking a detailed history to elicit features of ischaemic chest pain together with careful physical examination and then investigating using well-established procedures such as exercise electrocardiography (ECG), functional imaging (e.g. radionuclide imaging, stress echocardiography) and the "gold standard" test - coronary angiography, are well described in any textbook of medicine or cardiology.

However, to formulate a service that combines these principles and to deliver them in a timely, accurate and cost-effective format is a major challenge to most clinicians. Furthermore, the emergence of more recent cardiovascular imaging modalities, namely intravascular ultrasound (IVUS), multislice computed tomography (MSCT) and cardiac magnetic resonance imaging (CMRI) also provide new perspectives in the assessment and diagnosis of CAD and offer the clinicians more options in choosing the most appropriate test for each individual patient.

In this review article, the conventional and newer procedures that are used to investigate and diagnose CAD and their current applications will be briefly discussed.

Non-invasive modalities

Exercise electrocardiography

Exercise ECG is usually the initial test of choice for the evaluation of patients with suspected cardiac chest pain. The indications of exercise electrocardiography to diagnose obstructive CAD as recommended by AHA/ACC 2002 Guideline Update for Exercise Testing1 are shown in Table 1. For obvious reasons, exercise ECG is inappropriate in patients who are unable to exercise (e.g the presence of peripheral vascular disease or osteoarthritis of the knees, etc.) and is of little diagnostic usefulness in patients with particular ECG abnormalities at rest (Table 1). Exercise ECG test is frequently performed in the outpatient settings and should be supervised by a physician. During the test, the physician should be nearby and available in case of emergency.2-3 Exercise ECG is a relatively safe procedure with a minor complication rate of about 2 % (mainly arrhythmias and hypotension).4 The rate of acute myocardial infarction or death is about 1 in 2500 tests.5

Table 1: 2002 Exercise testing guideline recommendation for diagnosing CAD

Class I

  1. Patients undergoing initial evaluation with suspected or known CAD, including those with complete right bundle-branch block or less than 1 mm of resting ST depression.
  2. Patients with suspected or known CAD, previously evaluated now presenting with significant changes in clinical status.
  3. Low-risk unstable angina patients 8-12 hours after presentation who had been free of active ischaemia or heart failure symptoms.
  4. Intermediate-risk unstable angina patients 2-3 days after presentation who had been free of active ischaemic or heart failure symptoms.

Class IIa

  1. Intermediate-risk unstable angina patients who have initial cardiac markers that are normal, a repeat ECG without significant change, and cardiac markers 6 to 12 hours after the onset of symptoms that are normal and no other evidence of ischaemia during observation.

Class IIb 

  1. Patients with the following resting ECG abnormalities:
    - Pre-excitation (Wolff-Parkinson-White) syndrome
    - Electronically paced ventricular rhythm
    - 1mm or more of resting ST depression
    - Complete LBBB or any interventricular conduction defect with a QRS duration > 120 ms
  2. Patients with a stable clinical course who undergo periodic monitoring to guide treatment.

Class III

  1. Patients with severe comorbidity likely to limit life expectancy and/or candidacy for revascularization.2. High-risk unstable angina patients.


Exercise ECG is the least expensive non-invasive test for myocardial ischaemia. The costs of stress echocardiography and stress single-photon-emission computed tomography (SPECT) are at least 2 and 5 times as high, respectively;6 and those of newer tests e.g. MSCT, cardiovascular MRI are much higher. Several drugs can affect the results of exercise electrocardiography, including digoxin, beta-blockers, calcium channel blockers, vasodilators, etc. Beta-blockers and other anti-ischaemic drugs should be stopped about 2 days before exercise testing is performed as part of the diagnostic workup and initial risk stratification for patients with suspected CAD if possible.6 However, the withdrawal of these medications is not often feasible.

Data from a meta-analysis involving 147 studies and 24,074 patients indicated that as compared to coronary angiography, exercise ECG had a sensitivity of 68% and a specificity of 77% for detection of CAD.7 However, results varied markedly among studies, reflecting heterogeneity of criteria for abnormal results and various degrees of severity of coronary disease in the study populations. In patients without a high risk of extensive coronary diseases, the sensitivity of exercise ECG may be as low as 45%.8 Exercise testing is less sensitive in women than in male, and some data suggested that it may also be less specific.6

The interpretation of the results of an exercise ECG test as positive or negative on the basis of ECG changes alone, without consideration of other important parameters like patient's symptoms, exercise capacity and changes in blood pressure and heart rate, is to be avoided. One approach to integrating data from exercise ECG is through the use of Duke treadmill score (Table 2).9 This treadmill score is useful in helping clinicians to determine prognosis and decide whether to refer patients with suspected coronary disease for coronary angiography.

Table 2: Duke Treadmill Score

Duke Treamill score
= Duration of exercise (minutes) - (5 x maximal net ST-segment deviation during or after exercise) (mm) - (4 x the treadmill angina index) (see below)

The angina index = 0 if angina is absent during exercise, 1 if typical angina occurs during exercise, and 2 if angina is the reason for terminating exercise.

If Duke Treadmill score is greater than or equal to +5 = low risk (average annual mortality rate - 0.25%)

If Duke Treadmill score is less than -10 = high risk (average annual mortality rate - 5%)
Treadmill scores ranged from -25 (indicating the highest risk) to +15 (indicating the lowest risk).


Radionuclide imaging

Radionuclide imaging is a commonly used imaging technology in assessing patients with known or suspected ischaemic chest pain. Most radionuclide imaging in cardiology applications use SPECT to reconstruct anatomical slices of discrete thickness in standardized views. More complicated scanners for positron-emission tomography (PET) use multiple rings of stationary detectors that detect emissions from tracers, which can be used to determine regional myocardial blood flow and metabolic processes. However, PET scanners are more costly than those of SPECT and are not widely available for routine use.

SPECT requires the use of radioactive tracers. These tracers are labelled either with thallium TI 201 or technetium Tc99m and are used to assess myocardial perfusion and viability. The uptake of these agents by myocardial cells depends on both the perfusion and viability of that region of myocardium. The initial distribution of these tracers is proportional to myocardial blood flow, whereas so-called redistribution images, which are obtained 3-4 hours later, reflect myocardial viability and are independent of flow. A myocardial defect on an initial scan that subsequently resolves is an indicator of myocardium that is viable but ischaemic. A defect that is apparent on both scans suggests a region of myocardium that has died, usually as a result of previous myocardial infarction.

Ischaemia can be provoked with physical exercise or pharmacological agents. Dobutamine is a positive inotropic agent that provokes ischaemia by increasing myocardial workload, whereas adenosine and dipyridamole are vasodilators that unmask coronary stenoses by "coronary steal", i.e. by diverting blood flow to coronary arteries that are not diseased. All three drugs are useful in patients who are unable to perform physical exercise.

As compared to coronary angiography, the sensitivity and specificity of SPECT in detecting CAD are 88% (range from 73-98%) and 77% (53-96%) respectively.10 The diagnostic performance of technetium-based agents is similar to that of thallium.6 The diagnostic yield of the above pharmacological agents with respect to radionuclide perfusion imaging is similar and is also similar to that obtained with physical exercise.11 Nevertheless, dobutamine has not been studied as extensively as the two vasodilators; it is recommended for use when there are contraindications to the use of adenosine or dipyridamole (e.g. allergy, asthma, heart block, etc.).6 Same as exercise ECG, concurrent use of beta blockers and other anti-ischaemic medications may reduce the sensitivity of radionuclide imaging for the detection of CAD. Such agents should be stopped 4-5 half-lives before testing.6

Radionuclide imaging also provides prognostic information as from exercise ECG in both men and women.12-14 However, same as exercise ECG, radionuclide perfusion imaging is less accurate in women than in men. Some studies suggested that the better imaging properties of technetium 99m sestamibi may make it a superior agent for the evaluation of obese patients or women with large breast or breast implants.15

Stress echocardiography

Stress echocardiography is another imaging modality available for the investigation of ischaemic chest pain. It involves either exercise or pharmacological agents to induce ischaemia.16 Echocardiographic images acquired while patient is at rest and immediately during pharmacological stress using dobutamine or dipyridamole (or immediately after stress for patient undergoing exercise treadmill stress) are compared side by side (Figure 1). A study is considered positive if regional wall motion abnormalities develop with stress in previously normal segment or deteriorate in a segment that was already abnormal at baseline. In addition to providing information on the location and extent of jeopardized myocardium, this test also gives insight into left ventricular and valvular functions.

Figure 1: Images from a stress echocardiographic study. Regional wall motion abnormalities are always better shown by digital cine loops.
Dec_2006_Update_Article-_Figure_1

The diagnostic performance of stress echocardiography varies widely, with a sensitivity of 76% (range from 40-100%) and a specificity of 88% (80-95%) for the detection of CAD while using coronary angiography as the "gold standard".10 As compared to radionuclide perfusion imaging, data had shown that the sensitivity of stress echocardiography is slightly lower.10,17 As is true of other non-invasive test for ischaemia, the test has a higher sensitivity for multivessel disease (~90%) than single vessel disease (56%).6,18 Pooled data had found that exercise echocardiography is more specific than exercise SPECT.19 Dobutamine and dipyridamole stress echocardiography have similar diagnostic yields.20

Apart from being used as a diagnostic test for ischaemic chest pain, stress echocardiography can further provide important prognostic information and had been validated by long-term studies. Among medically treated patients, the 4-year rate of infarction free survival was lower in patients with positive tests than in those with negative tests (87% vs 97%).18 These data suggested that patients with positive tests have a better prognosis if they are treated invasively.18 A negative exercise echocardiography is reassuring, as the rate of survival without cardiac events is 99.2% at 1 year and 97.4% at 3 years.21

Rapid development of stress echocardiography imaging using ultrasound contrast agents (basically made up of microbubbles able to traverse pulmonary and systemic circulation) now may allow simultaneous assessment of both myocardial function and perfusion.22-23 Although myocardial contrast stress echocardiography is not currently used as a routine test for the assessment of CAD, it is likely that it will become an integral part of stress echocardiography in the future.

Multislice computed tomography (MSCT)

Cardiac MSCT have gained enormous popularity as a test for the assessment of ischaemic chest pain and a non-invasive alternative to coronary angiography over the recent years. With the swift advances of technology in MSCT (newer scanners have 16 or 64 detectors), there are significant improvements in its speed and spatial resolution (as high as 0.4 x 0.4 x 0.5 mm) as compared to those of previous generations. Together with the ability to time the scan by synchronizing with the cardiac cycle using electrocardiogram (ECG), current MSCT has minimized the cardiac-motion artifacts and allows for precise analysis of cardiac anatomy (Figure 2).

Figure 2: 3D reconstructed MSCT film showing proximal LAD and LCx stenosis
Dec_2006_Update_Article-_Figure_2

The performance of MSCT coronary angiography involves radiation exposure (as high as 10-20 mSV) and requires the administration of intravenous contrast; a patient who is allergic or intolerant to such agents (e.g. significant renal impairment and pregnancy) should avoid this examination. Breath holding of short duration (~ 5-10 second) is also mandatory. Inability to hold the breath will increase the likelihood of poor scan quality due to respiratory motion artifacts. Regular heart rhythm and slow heart rate (heart rate ~ 60-80 bpm) are also crucial for capturing optimal images of the coronary arteries.

MSCT coronary angiography is now used clinically to assess coronary vessels and bypass grafts non-invasively. Numerous studies have been conducted on the accuracy of MSCT angiography in cases of known or suspected CAD.24-28 Comparing sensitivity and specificity of MSCT in detecting coronary lumen obstruction of > 50% with invasive coronary angiography ranged from 82-100% and 78 to 98% respectively. The real strength of MSCT appears to be its high negative predictive value which, in the most recent studies, ranged from 95-99% among patients at intermediate-to-high risk of CAD.

More recently, appropriateness reviews were conducted by the American College of Cardiology Foundation (ACCF) together with key specialty and subspecialty societies for the application of MSCT coronary angiography in the evaluation of chest pain and had determined that such test is appropriate in patients who had any of the following clinical features: intermediate pre-test probability of CAD, uninterpretable resting ECG (see Table 1), inability to exercise, previously uninterpretable or equivocal stress test (exercise, perfusion, or stress echo).29 There is no long-term data regarding outcomes for patients who have negative tests, although there will be forthcoming shortly. Therefore, patients who have chest pain but are at low-to-moderate cardiovascular risk or equivocal stress tests are ideal candidates for MSCT coronary angiography. Indeed, for the particularly anxious patient with atypical chest pain, the combination of a low-risk stress test and a negative MSCT coronary angiogram is an impressive tool for reassurance.

Electron beam computed tomography (EBCT) is another subtype of computed tomography which had long been available for detection of coronary calcium deposits as a surroagte marker for coronary atherosclerosis. EBCT does not require iodinated contrast and the only identifiable component of the coronary artery is calcium within an atherosclerotic plaque. While the detection of high calcium content within the coronary artery (expressed as high calcium score) is sensitive for the presence of significant CAD, the ACC/AHA Consensus Panel did not recommend such test for diagnosing obstructive CAD because of its low specificity.30 In short, calcium scoring by EBCT is probably better used as a risk factor indicator for CAD rather than as a diagnostic test.

Cardiac magnetic resonance imaging (CMRI)

Rapid progress has been made in CMRI over the past 10 years and has firmly established itself as a reliable and clinically important technique for the assessment of CAD by means of coronary magnetic resonance angiography (CMRA) and first-pass contrast enhanced CMRI. CMRI is non-invasive, has high spatial resolution and does not use ionising radiation. MRI is based on the principle of nuclear magnetic resonance. In very simplistic terms, images are derived from signals by protons in body water. Such proton behaves like a small magnet and will therefore align parallel and anti-parallel to the direction of the primary magnetic field, with a small excess of parallel protons that gives rise to a net magnetisation vector. By application of a secondary temporary radiofrequency pulse, this net vector can be altered and once the pulse is discontinued, the vector reverts back to its former position, releasing signal in the form of radiowaves. Further elaboration of the underlying mechanism and techniques of CMRI is beyond the scope of this article and had been described elsewhere.

Currently, CMRA is much less commonly used than MSCT angiography to detect CAD as there is limited evidence that CMRA can accurately do so.31 Indeed, CMRA had been judged to be an inappropriate test for the evaluation of patients with chest pain except in case of suspected coronary anomalies by ACCF and other related specialty and subspecialty societies.29

On the other hand, first-pass perfusion CMRI has been reported to have high diagnostic accuracy for detection of CAD. First-pass perfusion CMRI assesses myocardial perfusion reserve (an indirect measures of coronary flow) by establishing the signal intensity-time curves before and after pharmacologically induced hyperaemia. The sensitivity, specificity and diagnostic accuracy are 90%, 83% and 87% respectively for the detection of CAD as compared to coronary angiography.32 CMRI perfusion reserve improves after revascularization.33 Further developments in imaging protocol (multislice techniques with fast near-real-time sequences) had improved spatial and temporal resolution of the scan and have resulted in near-complete myocardial coverage, making first-pass CMRI perfusion a viable alternative to scintigraphy. According to the latest guidelines,29 perfusion CMRI is an appropriate test in assessing patients with chest pain who had any of the following: intermediate pre-test probability of CAD, uninterpretable ECG (see Table 1) or inability to exercise. Its use is also appropriate in the evaluation of the functional significance of an intermediate coronary stenosis shown on MSCT or conventional invasive coronary angiography.

Invasive modalities

Coronary angiography

Invasive coronary angiography was first introduced in the late 1950s and the utilization of coronary angiography had increased exponentially since then. Coronary angiogram is performed by inserting a specialized, preshaped catheter into a major artery percutaneously (most commonly via the superficial femoral artery a few centimetres below the mid-point of inguinal ligament), and with minimal manipulation, the catheter will then engage into the coronary ostia. Contrast agent is then injected into the coronary arteries and thus become opacified. The images of the coronary arteries will then be captured by the digital X ray camera (Figure 3). More than 4 million coronary angiograms were performed in the United States each year. With current technology, it delivers digital images of superior spatial (0.2mm) and temporal (5ms) resolution. Coronary angiography is the "gold standard" test for diagnosing CAD.

Figure 3: A coronary angiogram showing a critical lesion in the first diagonal artery
Dec_2006_Update_Article-_Figure_3

Coronary angiography requires high level of technical competence and specific equipments, which makes it relatively expensive. It is associated with mild patient discomfort during the procedure and the risk of serious complications is <1/1000,34 hence restricted to a selected group of patients. Furthermore, coronary angiography has its own limitations; it is basically a "lumenogram" and provides relatively little details in regard to the nature and characteristics of the coronary plaques. Because of this problem, the use of complementary intravascular ultrasound during coronary angiography had greatly facilitated the cardiologist to measure and characterize coronary vessels and atherosclerotic plaques.

Intravascular ultrasound (IVUS)

IVUS is an invasive procedure which is performed during cardiac catheterization using miniature ultrasound probes mounted on the tip of a specialized coronary catheter. The IVUS probe emits high ultrasound frequencies and the ultrasound signal reflected from arterial wall structures is used to generate a grey scale image. The probe is placed beyond the target lesion site and the ultrasound catheter is then slowly pulled back during continuous imaging. This results in a series of images displaying 360o cross-sectional views of layers of the coronary artery (intima, media and adventitia) as well as the lumen.

Extensive experience has shown that IVUS is a safe, accurate and reliable method for assessment of the severity and morphology of coronary lesions.35 Using IVUS, some morphological features of atherosclerotic coronary plaques can be readily recognised. For example, soft plaque is mainly composed of echolucent tissue and correlates with a high lipid content and necrotic tissue; while calcific plaque is highly echogenic because of its calcium content. Other structure that can be viewed with IVUS includes intraluminal thrombus which is usually seen as a mass in the lumen, and intimal hyperplasia which appears as barely echogenic tissue within a stent.

The main clinical application of IVUS is in the placement of stent during percutaneous coronary intervention (PCI). The use of IVUS immediately before stent placement would provide strategic information on the exact length and size of the stent needed. After placement of the stent, IVUS also helps the operator in deciding whether additional balloon inflation is required if the stent was suboptimally expanded, and to look for post-stenting complication like stent edge dissection in which case additional stents may be needed to cover the new lesion. More importantly, the use of IVUS can improve PCI outcomes. Several studies had demonstrated that IVUS guided stenting using bare-metal stent had better lumen dimensions, with some reduction in restenosis and target lesion revascularization at follow-up as compared to that guided by conventional angiography.36-40

Conclusion

Various investigations available for the assessment of suspected ischaemic chest pain, whether with conventional tests like exercise ECG, radionuclide imaging and stress echocardiography, or with newer imaging modalities like MSCT, CMRI or coronary angiography complemented with IVUS, provide the precise diagnosis with good to excellent accuracy and the severity of the underlying CAD. Some investigation allows deeper insights into the mechanism of various aspects of CAD (e.g. IVUS in the understanding of ISR) and its implications in the diagnostic and therapeutic strategies in treating CAD.

To sum up, it is hoped that by choosing a series of most suitable tests (as recommended by the authors - see Figure 4) will allow the identification of those who are most at risk for adverse cardiovascular events and facilitate in choosing the most appropriate interventions and eventually improve their outcomes.

Figure 4: Suggested flowcharts for the assessment of patients with suspected ischaemic chest pain

Dec_2006_Update_Article-_Figure_4

Key messages

  1. By choosing the most suitable tests for patients suffering from suspected ischaemic chest pain will facilitate in deciding the most appropriate interventions and eventually improve their outcomes.
  2. Exercise ECG is still the initial test of choice for the evaluation of patients with suspected ischaemic chest pain who had interpretable ECGs and can exercise, but its sensitivity (68%) and specificity (77%) of detecting CAD are only moderate.
  3. Both SPECT and stress echocardiography offer better sensitivity (88% and 76%) and specificity (77% and 88%) for the diagnosis of CAD in comparison to exercise ECG. Their main usage is in patients who are indicated but unsuitable for exercise ECG (e.g. abnormal baseline ECGs and inability to exercise).
  4. MSCT and first-pass perfusion CMRI are newer generation of imaging modalities which provide even better accuracy in detecting CAD than SPECT and stress echocardiography.
  5. Coronary angiography is the "gold standard" test for diagnosing CAD. It requires high level of technical competence and specific equipments, which makes it relatively expensive. Since it is invasive, the risk of serious complications is < 1/1000.
  6. IVUS is another invasive imaging modality performed during cardiac catheterization. The main clinical application of IVUS is during the performance of percutaneous coronary intervention (PCI). IVUS can provide strategic information to facilitate the interventional cardiologist to optimize the immediate result of the operation.
  7. All the above imaging modalities have its own advantages and disadvantages and the choice of individual test will depend on patient's preference, the availability of clinical expertise and resources, and the caring clinician's familiarity of the tests.

John T H Wong, MBBS (Hons)(HK), MRCP (UK), FHKCP, FHKAM (Medicine)
Specialist Medical Officer (Cardiology)

Andy W K Chan, MBBS (HK), FRCP (Lond), FHKCP, FHKAM (Medicine)
Consultant Cardiologist and Head,

Division of Cardiology, Department of Medicine and Geriatrics, United Christian Hospital.

Correspondence to: Dr Andy W K Chan, Division of Cardiology, United Christian Hospital, Kwun Tong, Kowloon, Hong Kong.


References
  1. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the ACC/AHA Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 2002; 106:1883-1892.
  2. Gibbons RJ, Balady GJ, Beasley JW, et al. ACC/AHA guidelines for exercise testing: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). J Am Coll Cardiol 1997; 30:260-331.
  3. Pina IL, Balady GJ, Hanson P, et al. Guidelines for clinical exercise testing laboratories: a statement for healthcare professionals from the Committee on Exercise Testing and Cardiac Rehabilitation, American Heart Association. Circulation 1995; 91: 912-921.
  4. Poon TL, Leung KF, Chan WK, et al. Complications of exercise ECG test. Journal of Hong Kong College of Cardiology 2003;11:135.
  5. Stuart RJ Jr, Ellestad MH. National survey of exercise stress testing facilities. Chest 1980;77:94-97.
  6. Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 1999;33:2092-2197. [Erratum, J Am Coll Cardiol 1999;34:314.]
  7. Gianrossi R, Detrano R, Mulvihill D, et al. Exercise-induced ST depression in the diagnosis of coronary artery disease: a meta-analysis. Circulation 1989;80:87-98.
  8. Froelicher VF, Lehmann KG, Thomas R, et al. The electrocardiographic exercise test in a population with reduced workup bias: diagnostic performance, computerized interpretation, and multivariable prediction. Ann Intern Med 1998;128:965-974.
  9. Mark DB, Shaw L, Harrell EF Jr, et al. Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. N Engl J Med 1991;325:849-853.
  10. Garber AM, Solomon NA. Cost effectiveness of alternative test strategies for the diagnosis of coronary artery disease. Ann Intern Med 1999;130:719-728.
  11. Ritchie JL, Bateman TM, Bonow RO, et al. Guidelines for clinical use of cardiac radionuclide imaging: report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic Cardiovascular Procedures (Committee on Radionuclide Imaging), developed in collaboration with the American Society of Nuclear Cardiology. J Am Coll Cardiol 1995;25:521-547.
  12. Hachamovitch R, Berman DS, Kiat H, et al. Exercise myocardial perfusion SPECT in patients without known coronary artery disease; incremental prognostic value and use in risk stratification. Circulation 1996;93:905-914.
  13. Berman DS, Hachamovitch R, Kiat H, et al. Incremental value of prognostic testing in patients with known or suspected ischaemic heart disease: a basis for optimal utilization of exercise technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography. J Am Coll Cardiol 1995;26:639-647. [Erratum, J Am Coll Cardiol 1996; 27:756.]
  14. Hachamovitch R, Berman DS, Kiat H, et al. Effective risk stratification using exercise myocardial perfusion SPECT in women: gender-related differences in prognostic nuclear testing. J Am Coll Cardiol 1996;28:34-44.
  15. Smanio PE, Watson DD, Segalla DL, et al. Value of gating of technetium-99 sestamibi single-photon emission computed tomographic imaging. J Am Coll Cardiol 1997;30:1687-1692.
  16. Rodgers GP, Ayanian JZ, Balady G, et al. American College of Cardiology/American Heart Association clinical competence statement of stress testing: a report of the American College of Cardiology/American Heart Association /American College of Physicians-American Society of Internal Medicine Task Force on Clinical Competence. Circulation 2000;102:1726-1738.
  17. Cheitlin MD, Alpert JS, Armstrong WF, et al. ACC/AHA guidelines for the clinical application of echocardiography; a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography): developed in collaboration with American Society of Echocardiography. Circulation 1997; 95:1686-1744.
  18. Cortigiani L, Picano E, Landi P, et al. Value of pharmacologic stress echocardiography in risk stratification of patients with single-vessel disease: a report from Echo-Persantine and Echo-Dobutamine International Cooperative Studies. J Am Coll Cardiol 1998;32:69-74.
  19. Fleischmann KE, Hunink MG, Kuntz KM, et al. Exercise echocardiography or exercise SPECT imaging? A meta-analysis of diagnostic test performance. JAMA 1998;280:913-920.
  20. Pingitore A, Picano E, Varga A, et al. Prognostic value of pharmacological stress echocardiography in patients with known or suspected coronary artery disease: a prospective, large scale, multicenter, head-to-head comparison between dipyridamole and dobutamine test. J Am Coll Cardiol 1999;34: 1769-1777.
  21. McCully RB, Roger VL, Mahoney DW, et al. Outcome after normal exercise echocardiography and predictors of subsequent cardiac events: follow-up of 1,325 patients. J Am Coll Cardiol 1998;31:144-149.
  22. Porter TR, Xie F, Silver M, et al. Real-time perfusion imaging with low mechanical index pulse inversion Doppler imaging. J Am Coll Cardiol 2001; 37:748-753.
  23. Senior R, Lepper W, Pasquet A, et al. Myocardial perfusion assessment in patients with medium probability of coronary artery disease and no prior myocardial infarction: comparison of myocardial contrast echocardiography with 99m Tc-SPECT. Am Heart J 2004;147:1100-1105.
  24. Hoffmann MH, Shi H, Schmitz BL, et al. Noninvasive coronary angiography with multislice computed tomography. JAMA 2005; 293: 2471-2478.
  25. Leschka S, Alkadhi H, Plass A, et al. Accuracy of MSCT coronary angiography with 64-slice technology: first experience. Eur Heart J 2005; 15:1482-1487.
  26. Mollet NR, Cademartiri F, Krestin GP, et al. Improved diagnostic with 16-row multi-slice computed tomography coronary angiography. J Am Coll Cardiol 2005; 45: 128-132.
  27. Raff GL, Gallagher MJ, O'Neill WW, et al. Diagnostic accuracy of noninvasive coronary angiography using 64-slice spiral computed tomography. J Am Coll Cardiol 2005;46:552-557.
  28. Mollet NR, Cademartiri F, Mieghem C, et al. High-Resolution Spiral Computed Tomography Coronary Angiography in Patients Referred for Diagnostic Conventional Coronary Angiography. Circulation 2005;112: 2318-2323.
  29. Hendel RC, Patel MR, Kramer CM, et al. ACCF/ACR/SCCT SCMR/ASNC/NASCI/SCAI/SIR Appropriateness Criteria for Cardiac Computed Tomography and Cardiac Magnetic Resonance Imaging. J Am Coll Cardiol 2006;48;(in press).
  30. O'Rourke RA, Brundage BH, Froelicher VF, et al. American College of Cardiology/ American Hear Association Consensus Document on Electronic Beam Computed Tomography for the Diagnosis and Prognosis of Coronary Artery Disease. J Am Coll Cardiol 2000; 36: 326-340.
  31. Kim WY, Danias PG, Stuber M, et al. Coronary magnetic resonance angiography for the detection of coronary stenoses. N Engl J Med 2001; 345:1863-1869.
  32. Al-Saadi N, Nagel E, Gross M, et al. Noninvasive Detection of Myocardial Ischaemia From Perfusion Reserve Based on Cardiovascular Magnetic Resonance. Circulation 2000;101:1379-1383.
  33. Al-Saadi N, Nagel E, Gross M, et al. Improvement of myocardial perfusion reserve early after coronary intervention; assessment with cardiac magnetic resonance imaging. J Am Coll Cardiol 2000;36:1557-1564.
  34. Madigan NP, Sanfelippo JF, Curtis JJ, et al. Coronary angiography reviewed. Part II. Complication rate and management of the 'high risk' patient. Mo Med 1980;77:401-405.
  35. Hausmann D, Erbel R, Alibelli-Chermarin MJ, et al. The safety of intracoronary ultrasound: a multicenter survey of 2207 examinations. Circulation 1995;91:623-630.
  36. Schiele F, Meneveau N, Vuillemenot A, et al. The REStenosis after Ivus-guided STenting (RESIST) study Group. Impact of intravascular ultrasound guidance in stent deployment on 6-month restenosis rate: a multicenter, randomized study comparing two strategies - with and without intravascular ultrasound guidance. J Am Coll Cardiol 1998;32:320-328.
  37. Schiele F, Meneveau N, Seronde MF, et al. Medical costs of intravascular ultrasound optimization of stent deployment: results of the multicentrer randomized REStenosis after Ivus-guided STenting (RESIST) study. Int J Cardiovasc Intervent 2000;3:207-213.
  38. Mudra H, di Mario C, de Jaegere P, et al. Randomized comparison of coronary stent implantation under ultrasound or angiographic guidance to reduce stent restenosis (OPTICUS study). Circulation 2001;104;1343-1349.
  39. Oemrawsingh PV, Mintz GS, Schalij MJ, et al. Intravascular ultrasound guidance improves angiographic and clinical outcome of stent implantation for long coronary artery stenoses: final results of a randomized comparison with angiographic guidance (TULIP study). Circulation 2003;107:62-67.
  40. Chan TF, Chan WK. Restenosis rate of intravascular ultrasound guided percutaneous coronary intervention. Journal of Hong Kong College of Cardiology 2006; 14: 51.